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Introduction
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline (Cummings, 2004) . Previous studies have repeatedly identified that mitochondrial dysfunction is a hallmark brain pathology underlying AD synaptic injury and neuronal death (Reddy et al., 2010; Wang et al., 2014; Zhu et al., 2013) . Compromised mitochondrial oxidative phosphorylation (OXPHOS) constitutes a characteristic mitochondrial deficit in AD brains, resulting in lowered ATP production and increased oxidative stress, and eventually cell death (Du et al., 2012; Reddy, 2006; Reddy and Beal, 2008) . The detailed mechanisms of OXPHOS impairment in AD remain as a long-standing scientific issue. But emerging evidence has accentuated the role of mitochondrial F1Fo ATP synthase dysfunction in AD-related mitochondrial OXPHOS failure (Beck et al., 2016) .
Mitochondrial F1Fo ATP synthase is the executive site for ADP phosphorylation (He et al., 2018; Rubinstein et al., 2003) . The dysfunction of this critical mitochondrial enzyme leads to disrupted OX-PHOS and progressive ATP depletion. It is suggested that the AD-related F1Fo ATP synthase deregulation is strongly associated with the aberrations of its key subunit, oligomycin sensitivity conferring protein (OSCP) (Beck et al., 2016) . OSCP is part of the peripheral stalk of F1Fo ATP synthase and plays a vital role in maintaining the structural stability of F1Fo complex (Carbajo et al., 2007) . Decreased expression of OSCP and the physical interaction of OSCP with amyloid β (Aβ) cause the loss of OSCP function, culminating in the deregulation of F1Fo ATP synthase in AD-related conditions (Beck et al., 2016) . In this regard, to determine the causative factors for such OSCP dysfunction is of paramount importance to understand mitochondrial OXPHOS defects in AD.
Intriguingly, a previous study on aging mice has shown an unexpected regulation on OSCP expression by Cyclophilin D (CypD; gene name: Ppif), which is evidenced by the observation that the brain agingrelated OSCP loss is rescued by genetic depletion of CypD (Gauba et al., 2017) . Given the close relationship of brain aging and AD, it is possible that decreased OSCP expression levels in AD brains are as well a result of CypD effect as increased CypD expression levels are a determined AD brain pathology (Du et al., 2008; Du et al., 2011) . Furthermore, CypD has the capacity to bind both OSCP (Beutner et al., 2017; Giorgio et al., 2009) and Aβ (Du et al., 2008; Du et al., 2011) . Of note, the interaction of CypD with OSCP could potentiate F1Fo complex uncoupling (Gauba et al., 2017; Giorgio et al., 2009) 
